Alacris Theranostics | GenomeWeb

Alacris Theranostics

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

Researchers plan to develop a device that supports nucleic acid sequencing and protein sequencing using plasmonic nanostructures.

Alacris' ModCell approach matches patients with appropriate therapies. 

NEW YORK (GenomeWeb News) – Alacris Theranostics today said that is has gained Illumina CSPro certification for next-generation sequencing.

NEW YORK (GenomeWeb News) – German firm Alacris Theranostics today announced a deal with GlaxoSmithKline for the application of Alacris' Modcell System for drug stratification.

ModCell uses a patient's normal genomic data as well as the genomic and transcriptomic profiles of the patient's tumor to generate object-oriented models that can be used to personalize cancer treatments.

Alacris Theranostics is using whole-genome sequence analysis to develop individualized cancer therapies while EyeSense is developing ophthalmic diagnostic systems for glucose monitoring of diabetes patients.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.